ME Therapeutics Holdings Inc.’s common shares are approved for listing on the Canadian Securities Exchange, effective Oct. 12, 2023, and will commence trading on the CSE at the market open on the listing date under the symbol METX.
On Oct. 4, 2023, ME Therapeutics was issued a receipt for its final long-form prospectus dated Sept. 29, 2023, which is available under the company’s profile on SEDAR+.
As of the listing date, ME Therapeutics has 23,561,105 shares outstanding. An aggregate of 18,727,772 shares are subject to escrow restrictions, of which: (i) 14,999,994 shares (including 12,525,429 shares which are also subject to escrow pursuant to National Policy 46-201) are subject to restrictions such that 10 per cent of these shares will be released on the listing date, and an additional 30 per cent released on the dates that are nine, 18 and 27 months after the listing date; (ii) one million shares are subject to restrictions such that 25 per cent of these shares will be released on the listing date and the remaining 75 per cent will be released on the date that is six months after the listing date; and (iii) 15,253,207 shares (including 12,525,429 shares which are also subject to the voluntary escrow noted above) are subject to escrow restrictions pursuant to National Policy 46-201, whereby 10 per cent are released on listing and an additional 15 per cent released on the dates that are six, 12, 18, 24, 30 and 36 months after the listing date.
ME Therapeutics Holdings Inc.
ME Therapeutics is an early-stage, Vancouver-based, biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. The company’s main focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells in order to enhance anti-tumour immunity.
ON BEHALF OF THE BOARD
“Salim Dhanji” Dr. Salim Dhanji Chief Executive Officer and Director For further information, please contact: Dr. Salim Dhanji
Telephone: (236) 516-7714
Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
This news release includes certain “forward‐looking statements” under applicable Canadian securities legislation. Forward‐looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward looking statements in this news release include, but are not limited to, statements regarding the trading of the Shares on the CSE, the intended benefits and applications of the Company’s technology, and the Company’s plans for development of its business. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company, including the risks that the Shares may not become listed on the CSE and that the Company’s business may not develop as set out in this news release. No assurance can be given that any of the events anticipated by the forwardlooking statements will occur or, if they do occur, what benefits the Company will obtain from them. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐looking statements. The Company disclaims any intention or obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as required by law.
© 2023 Canjex Publishing Ltd. All rights reserved.
